Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.

Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31.

PMID:
23903369
2.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.

Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.

PMID:
25600953
3.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.

Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.

4.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators..

Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.

5.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.

Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.

PMID:
21333426
6.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators..

N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.

7.

Review of tolvaptan for autosomal dominant polycystic kidney disease.

Baur BP, Meaney CJ.

Pharmacotherapy. 2014 Jun;34(6):605-16. doi: 10.1002/phar.1421. Epub 2014 Apr 7. Review.

PMID:
24706579
8.

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S.

Clin Exp Nephrol. 2015 Oct;19(5):867-77. doi: 10.1007/s10157-015-1086-2. Epub 2015 Feb 7.

PMID:
25663351
9.

Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?

Reddy B, Chapman AB.

Am J Kidney Dis. 2015 Jun;65(6):811-3. doi: 10.1053/j.ajkd.2015.03.004. No abstract available.

PMID:
26003607
11.

Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.

Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1749-56. doi: 10.2215/CJN.09941014. Epub 2015 Jul 31.

12.

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Blair HA, Keating GM.

Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x. Review.

PMID:
26407729
13.

Role of vasopressin antagonists.

Torres VE.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Review.

14.

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W.

Nephrol Dial Transplant. 2016 Mar;31(3):337-48. doi: 10.1093/ndt/gfv456. Epub 2016 Jan 29. Review.

15.

Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.

Tominaga N, Kida K, Matsumoto N, Akashi YJ, Miyake F, Kimura K, Shibagaki Y.

Clin Nephrol. 2015 Jul;84(1):29-38. doi: 10.5414/CN108457.

PMID:
25997504
16.

The efficacy of tolvaptan as a diuretic for chronic kidney disease patients.

Tanaka A, Katsuno T, Ozaki T, Sakata F, Kato N, Suzuki Y, Kosugi T, Kato S, Tsuboi N, Sato W, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S.

Acta Cardiol. 2015 Apr;70(2):217-23.

17.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2013 Sep 17;159(6):382-9. doi: 10.7326/0003-4819-159-6-201309170-00004.

18.

Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.

Devuyst O, Torres VE.

Curr Opin Nephrol Hypertens. 2013 Jul;22(4):459-70. doi: 10.1097/MNH.0b013e3283621510. Review.

PMID:
23736843
19.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators..

Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.

PMID:
26912543
20.

Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y.

J Pharmacol Exp Ther. 2014 May;349(2):258-67. doi: 10.1124/jpet.114.213256. Epub 2014 Feb 25.

Supplemental Content

Support Center